HER2-positive metastatic breast cancer treatment granted Priority Review
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
List view / Grid view
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
The EMA CHMP has given a positive opinion for marketing authorisation approval to seven medicines following its October meeting.
Marketing authorisation in the EU for Baqsimi, the first non-injectable treatment for very low levels of blood sugar, has been recommended by an EMA committee.
A new report has said the osteoarthritis therapeutics market is estimated to grow due to rapid increase in the geriatric and obese population.
Reyvow (lasmiditan), for the treatment of acute migraine, has received approval from the FDA following success in clinical trials.
Research has revealed that the global female infertility pharmaceutical market will increase to be worth $2.5 billion by the end of the forecast period.
Researchers have revealed the top 10 drugs by annual revenue in 2025. Here, we investigate the indications that necessitate these treatments and the delivery systems they employ.
A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
California’s state governor has signed a bill which will stop drug makers from paying generic drug producers to stay off the market.
Despite plans to lower drug prices in the US, political divisions have muddied the waters. This article examines the efforts made by those involved and the possibilities of their success.
The global pharma contract development and manufacturing organisation (CDMO) outsourcing market is predicted to grow.
The UK Competition and Markets Authority has alleged that Aspen paid two other pharmaceutical companies to ensure they were the only supplier of a drug to the NHS.
The government has announced new measures to prevent parallel exporting to ease the supply chain, in an effort to reduce medicine shortages.
A survey of pharmacists has discovered that UK pharmacies experienced shortages across all 36 medicine categories in the last six months.
The UK National Audit Office has released a report which has found that medicine supply to the UK will be delayed in the event of a no-deal Brexit.